SASAKI Masanori

写真a

Affiliation

Institute of Regenerative Medicine, Department of Neural Regenerative Medicine

Job title

Associate Professor

Homepage URL

http://kaken.nii.ac.jp/d/r/20538136.ja.html

To the head of this page.▲

Research Experience 【 display / non-display 】

  • 2023.11
    -
    Now

    Sapporo Medical University   医学部 附属再生医学研究所   准教授

  • 2020.04
    -
    2023.10

    Sapporo Medical University   Research Institute for Frontier Medicine   准教授

  • 2012.08
    -
    2020.03

    Sapporo Medical University   Research Institute for Frontier Medicine   講師

  • 2012.01
    -
    2012.07

    Sapporo Medical University   Research Institute for Frontier Medicine   助教

To the head of this page.▲

Research Areas 【 display / non-display 】

  • Life sciences   Neurosurgery  

To the head of this page.▲

Affiliation 【 display / non-display 】

  • Sapporo Medical University   Institute of Regenerative Medicine   准教授  

To the head of this page.▲
 

Papers 【 display / non-display 】

  • Intravenous Infusion of Autologous Mesenchymal Stem Cells Expanded in Auto Serum for Chronic Spinal Cord Injury Patients: A Case Series.

    Ryosuke Hirota, Masanori Sasaki, Satoshi Iyama, Kota Kurihara, Ryunosuke Fukushi, Hisashi Obara, Tsutomu Oshigiri, Tomonori Morita, Masahito Nakazaki, Takahiro Namioka, Ai Namioka, Rie Onodera, Yuko Kataoka-Sasaki, Shinichi Oka, Mitsuhiro Takemura, Ryo Ukai, Takahiro Yokoyama, Yuichi Sasaki, Tatsuro Yamashita, Masato Kobayashi, Yusuke Okuma, Reiko Kondo, Ryo Aichi, Satoko Ohmatsu, Noritaka Kawashima, Yoichi M Ito, Masayoshi Kobune, Kohichi Takada, Sumio Ishiai, Toru Ogata, Atsushi Teramoto, Toshihiko Yamashita, Jeffery D Kocsis, Osamu Honmou

    Journal of clinical medicine   13 ( 20 )  2024.10  [International journal]

    　View Summary

    Objective: The safety, feasibility, and potential functional improvement following the intravenous infusion of mesenchymal stem cells (MSCs) were investigated in patients with chronic severe spinal cord injury (SCI). Methods: The intravenous infusion of autologous MSCs cultured in auto-serum under Good Manufacturing Practices (GMP) was administered to seven patients with chronic SCI (ranging from 1.3 years to 27 years after the onset of SCI). In addition to evaluating feasibility and safety, neurological function was evaluated using the American Spinal Injury Association Impairment Scale (AIS), International Standards for Neurological Classification of Spinal Cord Injury (ISCSCI-92), and Spinal Cord Independence Measure III (SCIM-III). Results: No serious adverse events occurred. Neither CNS tumors, abnormal cell growth, nor neurological deterioration occurred in any patients. While this initial case series was not blinded, significant functional improvements and increased quality of life (QOL) were observed at 90 and 180 days post-MSC infusion compared to pre-infusion status. One patient who had an AIS grade C improved to grade D within six months after MSC infusion. Conclusions: This case series suggests that the intravenous infusion of autologous MSCs is a safe and feasible therapeutic approach for chronic SCI patients. Furthermore, our data showed significant functional improvements and better QOL after MSC infusion in patients with chronic SCI. A blind large-scale study will be necessary to fully evaluate this possibility.

    DOI PubMed

  • Intravenous Infusion of Autologous Mesenchymal Stem Cells Expanded in Auto Serum for Chronic Spinal Cord Injury Patients: A Case Series

    Ryosuke Hirota, Masanori Sasaki, Satoshi Iyama, Kota Kurihara, Ryunosuke Fukushi, Hisashi Obara, Tsutomu Oshigiri, Tomonori Morita, Masahito Nakazaki, Takahiro Namioka, Ai Namioka, Rie Onodera, Yuko Kataoka-Sasaki, Shinichi Oka, Mitsuhiro Takemura, Ryo Ukai, Takahiro Yokoyama, Yuichi Sasaki, Tatsuro Yamashita, Masato Kobayashi, Yusuke Okuma, Reiko Kondo, Ryo Aichi, Satoko Ohmatsu, Noritaka Kawashima, Yoichi M. Ito, Masayoshi Kobune, Kohichi Takada, Sumio Ishiai, Toru Ogata, Atsushi Teramoto, Toshihiko Yamashita, Jeffery D. Kocsis, Osamu Honmou

    Journal of Clinical Medicine   13 ( 20 )  2024.10

    　View Summary

    Objective: The safety, feasibility, and potential functional improvement following the intravenous infusion of mesenchymal stem cells (MSCs) were investigated in patients with chronic severe spinal cord injury (SCI). Methods: The intravenous infusion of autologous MSCs cultured in auto-serum under Good Manufacturing Practices (GMP) was administered to seven patients with chronic SCI (ranging from 1.3 years to 27 years after the onset of SCI). In addition to evaluating feasibility and safety, neurological function was evaluated using the American Spinal Injury Association Impairment Scale (AIS), International Standards for Neurological Classification of Spinal Cord Injury (ISCSCI-92), and Spinal Cord Independence Measure III (SCIM-III). Results: No serious adverse events occurred. Neither CNS tumors, abnormal cell growth, nor neurological deterioration occurred in any patients. While this initial case series was not blinded, significant functional improvements and increased quality of life (QOL) were observed at 90 and 180 days post-MSC infusion compared to pre-infusion status. One patient who had an AIS grade C improved to grade D within six months after MSC infusion. Conclusions: This case series suggests that the intravenous infusion of autologous MSCs is a safe and feasible therapeutic approach for chronic SCI patients. Furthermore, our data showed significant functional improvements and better QOL after MSC infusion in patients with chronic SCI. A blind large-scale study will be necessary to fully evaluate this possibility.

    DOI

  • Intravenous infusion of auto-serum-expanded autologous mesenchymal stem cells into chronic severe brain injury patients

    Tomohiro Yamaki, Shinichi Oka, Satoshi Iyama, Masanori Sasaki, Rie Onodera, Yuko Kataoka-Sasaki, Takahiro Namioka, Ai Namioka, Masahito Nakazaki, Mitsuhiro Takemura, Ryo Ukai, Takahiro Yokoyama, Yuichi Sasaki, Tatsuro Yamashita, Masato Kobayashi, Misako Yamaguchi, Marina Fukino, Taro Takazawa, Megumi Hayasaka, Takamitsu Owaku, Mika Funakura, Shinji Onodera, Yoichi M. Ito, Masayoshi Kobune, Junji Kato, Sumio Ishiai, Jeffery D. Kocsis, Masaru Odaki, Yasuo Iwadate, Shigeki Kobayashi, Osamu Honmou

    Interdisciplinary Neurosurgery ( Elsevier BV )  36   101927 - 101927  2024.06

    DOI

  • Rehabilitation facilitates functional improvement following intravenous infusion of mesenchymal stem cells in the chronic phase of cerebral ischemia in rats.

    Tatsuro Yamashita, Masanori Sasaki, Yuichi Sasaki, Hiroshi Nagahama, Shinichi Oka, Yuko Kataoka-Sasaki, Ryo Ukai, Takahiro Yokoyama, Masato Kobayashi, Masafumi Kakizawa, Jeffery D Kocsis, Osamu Honmou

    Brain research   1825   148709 - 148709  2024.02  [International journal]

    　View Summary

    The primary objective of this study was to investigate the potential facilitating effects of daily rehabilitation for chronic cerebral ischemia following the intravenous infusion of mesenchymal stem cells (MSC) in rats. The middle cerebral artery (MCA) was occluded by intraluminal occlusion using a microfilament (MCAO). Eight weeks after MCAO induction, the rats were used as a chronic cerebral ischemia model. Four experimental groups were studied: Vehicle group (medium only, no cells); Rehab group (vehicle + rehabilitation), MSC group (MSC only); and Combined group (MSC + rehabilitation). Rat MSCs were intravenously infused eight weeks after MCAO induction, and the rats received daily rehabilitation through treadmill exercise for 20 min. Behavioral testing, lesion volume assessment using magnetic resonance imaging (MRI), and histological analysis were performed during the observation period until 16 weeks after MCAO induction. All treated animals showed functional improvement compared with the Vehicle group; however, the therapeutic efficacy was greatest in the Combined group. The combination therapy is associated with enhanced neural plasticity shown with histological analysis and MRI diffusion tensor imaging. These findings provide behavioral evidence for enhanced recovery by combined therapy with rehabilitation and intravenous infusion of MSCs, and may form the basis for the development of clinical protocols in the future.

    DOI PubMed

  • Actin Alpha 2, Smooth Muscle (ACTA2) Is Involved in the Migratory Potential of Malignant Gliomas, and Its Increased Expression at Recurrence Is a Significant Adverse Prognostic Factor.

    Takumi Hoshimaru, Naosuke Nonoguchi, Takuya Kosaka, Motomasa Furuse, Shinji Kawabata, Ryokichi Yagi, Yoshitaka Kurisu, Hideki Kashiwagi, Masahiro Kameda, Toshihiro Takami, Yuko Kataoka-Sasaki, Masanori Sasaki, Osamu Honmou, Ryo Hiramatsu, Masahiko Wanibuchi

    Brain sciences   13 ( 10 )  2023.10  [International journal]

    　View Summary

    Malignant glioma is a highly invasive tumor, and elucidating the glioma invasion mechanism is essential for developing novel therapies. We aimed to highlight actin alpha 2, smooth muscle (ACTA2) as potential biomarkers of brain invasion and distant recurrence in malignant gliomas. Using the human malignant glioma cell line, U251MG, we generated ACTA2 knockdown (KD) cells treated with small interfering RNA, and the cell motility and proliferation of the ACTA2 KD group were analyzed. Furthermore, tumor samples from 12 glioma patients who underwent reoperation at the time of tumor recurrence were utilized to measure ACTA2 expression in the tumors before and after recurrence. Thereafter, we examined how ACTA2 expression correlates with the time to tumor recurrence and the mode of recurrence. The results showed that the ACTA2 KD group demonstrated a decline in the mean motion distance and proliferative capacity compared to the control group. In the clinical glioma samples, ACTA2 expression was remarkably increased in recurrent samples compared to the primary samples from the same patients, and the higher the change in ACTCA2 expression from the start to relapse, the shorter the progression-free survival. In conclusion, ACTA2 may be involved in distant recurrence in clinical gliomas.

    DOI PubMed

display all >>

To the head of this page.▲

Misc 【 display / non-display 】

display all >>

To the head of this page.▲

Research Projects 【 display / non-display 】

  • 慢性期脳梗塞に対する骨髄幹細胞治療における至適リハビリ条件の探索

    基盤研究(C)

    Project Year :

    2024.04
    -
    2027.03
     

    山下 達郎, 佐々木 雄一, 佐々木 祐典, 鵜飼 亮, 岡 真一, 佐々木 優子, 本望 修, 中崎 公仁

  • Therapeutic strategies for cerebral infarction and spinal cord injury by activating plasticity throughout the central nervous system

    Grant-in-Aid for Scientific Research (B)

    Project Year :

    2024.04
    -
    2025.03
     

    本望 修, 佐々木 雄一, 福士 龍之介, 佐々木 祐典, 小原 尚, 鵜飼 亮, 小林 萬里, 山下 達郎, 横山 貴裕, 岡 真一, 佐々木 優子, 中崎 公仁

  • Bone marrow mesenchymal stem cell transplantation prevents concurrent progression of chronic kidney disease and associated cerebrovascular disease

    Grant-in-Aid for Scientific Research (C)

    Project Year :

    2023.04
    -
    2026.03
     

    長岡 由修, 飯塚 裕典, 寺田 光次郎, 津川 毅, 佐々木 祐典, 本望 修

  • Intravenous infusion of exosome for the treatment of neonatal hypoxic ischemic encephalopathy

    Grant-in-Aid for Scientific Research (C)

    Project Year :

    2023.04
    -
    2026.03
     

    寺田 光次郎, 津川 毅, 飯塚 裕典, 佐々木 祐典, 長濱 宏史, 坂井 拓朗, 本望 修

  • Development of novel treatments and elucidation of mechanisms for intractable epilepsy using bone marrow mesenchymal stem cells

    Grant-in-Aid for Scientific Research (C)

    Project Year :

    2022.04
    -
    2025.03
     

    福村 忍, 津川 毅, 佐々木 祐典, 長濱 宏史, 本望 修

display all >>

To the head of this page.▲